KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) Revenue (2016 - 2026)

Regeneron Pharmaceuticals (REGN) has disclosed Revenue for 18 consecutive years, with $3.6 billion as the latest value for Q1 2026.

  • For Q1 2026, Revenue rose 19.04% year-over-year to $3.6 billion; the TTM value through Mar 2026 reached $14.9 billion, up 5.92%, while the annual FY2025 figure was $14.3 billion, 0.99% up from the prior year.
  • Revenue hit $3.6 billion in Q1 2026 for Regeneron Pharmaceuticals, down from $3.9 billion in the prior quarter.
  • Across five years, Revenue topped out at $3.9 billion in Q4 2025 and bottomed at $50.0 million in Q1 2022.
  • Average Revenue over 5 years is $3.0 billion, with a median of $3.4 billion recorded in 2023.
  • Year-over-year, Revenue tumbled 98.02% in 2022 and then surged 6224.2% in 2023.
  • Regeneron Pharmaceuticals' Revenue stood at $100.0 million in 2022, then soared by 3334.3% to $3.4 billion in 2023, then increased by 10.33% to $3.8 billion in 2024, then increased by 2.51% to $3.9 billion in 2025, then fell by 7.18% to $3.6 billion in 2026.
  • According to Business Quant data, Revenue over the past three periods came in at $3.6 billion, $3.9 billion, and $3.8 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.